{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Pexidartinib for Pain Relief in Tenosynovial Giant Cell Tumor"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were adults with symptomatic TGCT, randomized 1:1"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with symptomatic TGCT"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59)"
      },
      "Objective": {
        "score": 1,
        "evidence": "assessed the efficacy of pexidartinib in reducing pain in adults with tenosynovial giant cell tumor"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was a \u226530% decrease in weekly mean worst-pain NRS score with <30% increase in narcotic use from baseline to week 25"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was via an integrated web response system, with allocation concealment"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and assessors"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "randomized 1:1 to receive pexidartinib (n=61) or placebo (n=59)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Pain response was observed in 31% (19/61) of the pexidartinib group versus 15% (9/59) of the placebo group"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Pain response was observed in 31% (19/61) of the pexidartinib group versus 15% (9/59) of the placebo group (p=0.03)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included liver toxicity"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02371369"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}